RApport in 2021
by RApport
RApport is an online communications hub for members of the biotech community to share ideas, problems, and solutions.
By Anthony Quintano for NBC
December 22, 2021
As the year comes to a close, we’d like to thank you all for being among the first to join us on this platform. We look forward to sharing many more perspectives from across the industry in 2022, so share yours with us @rapport_bio on Twitter or on our LinkedIn page.
In case you missed it (or if you’d like to send a link to a colleague), we’ve compiled a list of RApport’s most popular stories of 2021, along with a few things we’ll be reading over our end-of-year break.
Top Stories of 2021
When drug prices are a Trojan Horse for other costs, we all lose, by Peter Kolchinsky: The way that hospitals benefit from inflated list prices is a common theme across different kinds of drugs dispensed at hospitals and clinics across the country. This practice costs patients dearly and confuses the incentives behind drug development.
Rational design of molecular glues - the next frontier, by Jesse Chen: As more established targeted protein degradation companies produce promising data in the clinic, newcomers have been greeted with enthusiasm from the investment community. Jesse explains key intellectual and scientific breakthroughs & focuses on molecular glues as an exciting new frontier.
How to assassinate your start-up: a legal guide, by Sarah Reed: To be sure, none of these can ensure death with dignity, but most will speed your start-up’s demise – especially when taken as combination therapy.
Venture capital evolved to venture creation. Will it stay that way?, by Risa Stack: The so-called venture creation model has fully taken root, underpinned and enabled by biotech's longest-ever boom cycle and unprecedented sums of available capital.
Practical considerations for conducting a Series I IPO, Tess Cameron & Peter Kolchinsky: Biotech board members and management teams are increasingly asking how their companies can benefit from what RA Capital and others call a “Series I” IPO process (also known as a data-driven or logic-based IPO). Here we’ve compiled common questions and answers.
Since the summer of 2020, RA Capital has also been running webinars about the pandemic, our response, and, lately, whatever else we want. Take a look back through the catalog and see how far we’ve come at racap.com/ra-tv.
What We’re Reading (special holiday edition):
Tom: I’ll be finishing the dense but fascinating Generic: The Unbranding of Modern Medicine, which delves deep into how today’s generic drug market came to be. I’m also knee-deep in The Eye of the World, the first book in the Wheel of Time series, and expect more fantasy nerd stuff is waiting for me under the tree.
Jess: I’m taking a holiday break from healthcare reading and planning to finish The Writing of the Gods: The Race to Decode the Rosetta Stone. It’s the best nonfiction book I’ve read all year (and has already answered questions my linguistics degree never did!).
Chris: I plan to read Drew Magary’s “memoir of life after brain damage,” The Night the Lights Went Out, as well as whatever forgotten gems are hidden in the fifty or so tabs currently open in my Chrome browser.
Please click here for important RA Capital disclosures.
